{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:08:58Z","timestamp":1790197738339,"version":"4.1.0"},"reference-count":45,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Addiction"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aims<\/jats:title><jats:p>The aims of this study were to (1) estimate the effect of extended\u2010release naltrexone compared with placebo on alcohol consumption in patients with alcohol use disorder (AUD) and (2) conduct pre\u2010planned subgroup analyses to test whether being abstinent when initiating treatment (lead\u2010in abstinence) or the duration of treatment improves treatment efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Systematic review and random\u2010effects meta\u2010analysis of blinded randomized placebo\u2010controlled trials reporting the effect extended\u2010release naltrexone on alcohol consumption.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>Outpatient clinics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Participants<\/jats:title><jats:p>Seven trials evaluating a total of 1500 adults with AUD receiving monthly injections of either placebo or extended\u2010release naltrexone at doses of 150\u2013400\u00a0mg for 2\u20136\u00a0months and some form of behavioral therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements<\/jats:title><jats:p>Pooled weighted mean difference (WMD) in drinking days per month and heavy drinking days per month.<\/jats:p><\/jats:sec><jats:sec><jats:title>Findings<\/jats:title><jats:p>The WMD was \u22122.0 [95% confidence interval (CI)\u00a0=\u00a0\u22123.4, \u22120.6; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.03] in favor of extended\u2010release naltrexone for drinking days per month and \u22121.2 (95% CI\u00a0=\u00a0\u22120.2, \u22122.1; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.02) for heavy drinking days per month, indicating that treatment resulted in two fewer drinking days per month and 1.2 fewer heavy drinking days per month compared with placebo. Trials not requiring lead\u2010in abstinence and those lasting longer than 3\u00a0months reported larger reductions in heavy drinking days per month; WMD \u20132.0 (95% CI\u00a0=\u00a0\u22123.52, \u22120.48; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.01) and \u22121.9 (95% CI\u00a0=\u00a0\u22123.2, \u22120.5; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.01), respectively. In all cases, the <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> statistics (0\u20137.2%) did not suggest substantial heterogeneity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Extended\u2010release naltrexone reduces drinking days and heavy drinking days per month compared with placebo. Reductions are larger with a longer duration of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/add.15572","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T13:13:00Z","timestamp":1621948380000},"page":"271-281","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Effect of extended\u2010release naltrexone on alcohol consumption: a systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-0176","authenticated-orcid":false,"suffix":"IV","given":"Charles E.","family":"Murphy","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph C.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Montoy","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evans","family":"Whittaker","sequence":"additional","affiliation":[{"name":"UCSF Health Sciences Library University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Raven","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine University of California  San Francisco CA USA"},{"name":"Philip R. Lee Institute for Health Policy Studies University of California  San Francisco CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,28]]},"reference":[{"key":"e_1_2_6_2_1","volume-title":"Alcohol\u2010Related Disease Impact (ARDI)","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd11.130293"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2015.05.031"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13559"},{"key":"e_1_2_6_6_1","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"R\u00f6sner S.","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2001.tb02356.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2012.04054.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145704004997"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011127"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.17.2003"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08934"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000138"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.07.006"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2012.04452.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.009"},{"key":"e_1_2_6_17_1","volume-title":"Medicaid Coverage of Medication\u2010Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose. HHS Publication no. SMA\u201018\u20105093","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2018"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-019-00814-4"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11406"},{"key":"e_1_2_6_20_1","unstructured":"Cochrane Group. Data Collection Form (for RCTs). Available at:https:\/\/training.cochrane.org\/data\u2010collection\u2010form\u2010rcts(accessed 1 May 2020)."},{"key":"e_1_2_6_21_1","unstructured":"HigginsJ. P. T. GreenS. editors.Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. Cochrane Collaboration 2011:6.5.1\u20136.5.2. Available at:https:\/\/www.handbook.cochrane.org(accessed 15 December 2019).Chapter 6.1 sections 6.5.1 and 6.5.2"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-135"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4612-0357-5_3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.13.1617"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000139823.30096.52"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ALC.0000130804.08397.29"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.026"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-018-2241-z"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2014.12146.x"},{"key":"e_1_2_6_30_1","unstructured":"ALK21\u2013014: Efficacy and safety of Medisorb naltrexone (Vivitrol) after enforced abstinence;2011. Available at:http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00501631(accessed 10 December 2019)."},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.3628"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2014.03.007"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/jcp.0b013e31814ce50d"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/36.1.2"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602872"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12425"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12050"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200106000-00006"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2009.01024.x"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490903077929"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550490490480982"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/00019442-200506000-00008"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v4.i3.81"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.04.006"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13410"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14180"}],"container-title":["Addiction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/add.15572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/add.15572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T07:55:19Z","timestamp":1722239719000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/add.15572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,28]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1111\/add.15572"],"URL":"https:\/\/doi.org\/10.1111\/add.15572","archive":["Portico"],"relation":{},"ISSN":["0965-2140","1360-0443"],"issn-type":[{"value":"0965-2140","type":"print"},{"value":"1360-0443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,28]]},"assertion":[{"value":"2020-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}